The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Summary

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

Conditions

• Advanced Cancer
• Solid Tumor
• Haematological Malignancy

Interventions

DRUG

Alectinib

ALK

DRUG

Cobimetinib

MEK1, MEK2

DRUG

Vismodegib

Hedgehog

DRUG

Trastuzumab+Pertuzumab

HER2

DRUG

Entrectinib

NTRK/ ROS1, ALK

DRUG

Atezolizumab

PD-L1

DRUG

Vemurafenib

BRAF V600

DRUG

Regorafenib

KIT/BRAF, RET

DRUG

Apalutamide

AR

DRUG

Abemaciclib

CDK4/6

DRUG

Tepotinib

MET ex14

DRUG

Dabrafenib

RAF

DRUG

Trametinib

MEK1, MEK2

DRUG

Dabrafenib+Trametinib

RAF, MEK1, MEK2

DRUG

Pemigatinib

FGFR2

Sponsors & Collaborators

• Helsinki University Central Hospital

  lead OTHER

Principal Investigators

• Katriina Jalkanen, MD, PhD · Helsinki University Hospital Comprehensive Cancer Centre

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

100 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-12-10

Primary Completion

2026-11-25

Completion

2026-11-25

Countries

• Finland

Study Locations